Start With EYLEA. Stay With EYLEA.

The dosing schedules of EYLEA are shown in the context of visual acuity outcomes and mean number of injections according to clinical trial data.1-5 EYLEA offers flexible dosing options for certain approved indications in a single 2 mg formulation.1

Around 5.7 million doeses since launch. Around 635,000 eyes treated with EYLEA since launch. Around 5.7 million doeses since launch. Around 635,000 eyes treated with EYLEA since launch.

Dosing Driving Efficacy Outcomes Across All Indications1-5

1 Year (52 weeks) Wet AMD. 1 Year (52 weeks) DME. 2 Year (100 weeks) DME and DR in Patients with DME. 6 Months (24 weeks) Macular Edema following RVO. 1 Year (52 weeks) Wet AMD. 1 Year (52 weeks) DME. 2 Year (100 weeks) DME and DR in Patients with DME. 6 Months (24 weeks) Macular Edema following RVO.

EYLEA 2 mg Dosing Flexibility for Certain Approved Indications: Options for Your Patients' Individual Needs1

EYLEA dosing schedule for Wet AMD, DME, DR in DME, and Macular Edema following RVO. EYLEA dosing schedule for Wet AMD, DME, DR in DME, and Macular Edema following RVO.
Clinical Practice Information on Injection Administration and Injection Frequency/Outcomes
  • Injection Preparation and Administration

    9:55
  • Wet AMD Consistent Dosing With EYLEA

    6:36
  • DME Consistent Dosing With EYLEA

    6:58
Reimbursement Support

Get help navigating the reimbursement process. Find enrollment forms, sample appeal letters, and more.

See the details
Patient Support

We're committed to help ensure your eligible patients have access to EYLEA regardless of insurance or coverage.

Find support
News

Keep up to date on current EYLEA clinical information, events, and more.

Read the latest
Important Safety Information and Indications
  • EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information Important Prescribing Information

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. May 2017.
  2. Data on file. Regeneron Pharmaceuticals, Inc.
  3. Heier JS, Brown DM, Chong V, et al; for the VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
  4. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247-2254.
  5. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044-2052.